Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vantive Health LLC
With
University of Louisville
Vanderbilt University Medical Center
University of California, Davis
Gambro Renal Products, Inc.
Baxter Healthcare Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult subject ≥18 years of age undergoing chronic hemodialysis for end- stage renal disease (ESRD) three times a week for at least three months with a stable treatment prescription
Subject has no hospitalizations in previous three months for a significant illness related to a renal or dialysis problem except for vascular access surgery
Subject with an AV fistula or graft capable of routinely delivering a blood flow rate of 400 mL/min
You may not be if
Subject who is non-compliant with dialysis prescription
Subject whose hemodialysis schedule is not three times a week
Subject using a catheter for blood access
Subject who is not anticoagulated with heparin during hemodialysis
Subject with a current malignancy involving sites other than skin
Subject with a history of drug or alcohol abuse within the last six months
Subject who is believed to be unable to complete the entire study (e.g., due to a concurrent disease, life expectancy of less than a year, or scheduled kidney transplant
Subject who is pregnant
Subject who is considered incompetent to give an informed consent
Subject with a positive test for hepatitis B surface antigen within the past 30 days (testing for hepatitis B surface antigen is not required for subjects who have tested positive for hepatitis B antibody within the past year and any such patients will not be subject to this exclusion criterion)
Subject with known HIV infection (if this is not known, no HIV testing will be performed
Clareo Health | Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate
